Home › Research › Biomarkers
Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease
Ghahremani M, Leon R, Smith EE, Ismail Z.. Alzheimer's & dementia (Amsterdam, Netherlands), 2025-04-01
Topic: Amyloid, tau and blood-test diagnosis
Introduction Mild behavioral impairment (MBI), marked by late-onset persistent neuropsychiatric symptoms (NPS), may signal early dementia risk. While MBI is linked to previously established amyloid-beta (Aβ) and tau biomarkers, its association with plasma p-tau217, a promising blood-based biomarker for Alzheimer's disease (AD), remains unexplored. Here, we investigated the association between MBI and plasma p-tau217 in dementia-free individuals from the Alzheimer's Disease Neuroimaging Initiative. Methods MBI was defined using the Neuropsychiatric Inventory (NPI) data. Linear regression assessed the association between NPS status and continuous p-tau217 levels, while logistic regression modeled the association between NPS status and p-tau217 positivity, using a study-specific cutoff. Models adjusted for age, sex, education, and cognitive diagnosis. Results Among 101 participants (mean age = 72.0 ± 6.5; 44.6% female), those with MBI had higher plasma p-tau217 levels ( β = 36.4%; 95% confidence interval [CI]: 2.2-82.0, p = 0.04) and higher odds of being p-tau217 positive (odds ratio [OR] = 3.06, 95% CI: 1.14-8.70, p = 0.03) than MBI- participants. Discussion Findings support the role of MBI in AD risk stratification. Highlights Mild behavioral impairment (MBI) is linked to elevated plasma p-tau217, a specific Alzheimer's disease biomarker.MBI increases the odds of plasma p-tau217 positivity in dementia-free individuals.Findings support MBI as an early indicator for Alzheimer's disease risk.MBI assessment can improve biomarker-based screening and clinical trial efficiency.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ghahremani, M., Leon, R., Smith, E. E., & Ismail, Z. (2025). Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70119
Vancouver
Ghahremani M, Leon R, Smith EE, Ismail Z. Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands). 2025. doi:10.1002/dad2.70119. PMID: 40406748.
BibTeX
@article{ghahremani2025-40406748,
author = {Ghahremani, M. and Leon, R. and Smith, E. E. and Ismail, Z.},
title = {{Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2025},
doi = {10.1002/dad2.70119},
pmid = {40406748},
url = {https://doi.org/10.1002/dad2.70119}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Among 101 participants (mean age = 72.0 ± 6.5; 44.6% female), those with MBI had higher plasma p-tau217 levels ( β = 36.4%; 95% confidence interval [CI]: 2.2-82.0, p = 0.04) and higher odds of being p-tau217 positive (odds ratio [OR] = 3.06, 95% CI: 1.14-8.70, p = 0.03) than MBI- participants.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants101
- Effect size44.6%; 36.4%
- Evidence strengthLow
How this study scored 60/100
Published in a leading specialty journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 35 of the 58 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 101 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40406748) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 35 of the 58 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.